Not sure why you are saying ‘a capital raise will be needed’.
Leaving aside the current financials, which looked fine on 28 November & still do, the only thing that would be “nice” is a ‘capital injection’. But, as we both know, that can take so many forms & come from so many sources.
So, why don’t we just see what happens next. And I, for one, am not unhappy with Novartis’ (very tardy) notice - I’ve always seen them as hopelessly conflicted by their Incyte litigation, the ruxolitinib royalty $$ etc.
No material loss, as far as I’m concerned & it clears the decks.
Cheers
Ann: Update on Novartis Agreement, page-171
-
- There are more pages in this discussion • 680 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.15 |
Change
-0.105(8.37%) |
Mkt cap ! $1.313B | |||
| Open | High | Low | Value | Volume |
| $1.22 | $1.23 | $1.14 | $9.583M | 8.106M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 10000 | $1.15 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.16 | 25000 | 2 |
View Market Depth
| Last trade - 16.10pm 25/07/2024 (20 minute delay) ? |
| MSB (ASX) Chart |